Successful desensitization of three patients with hypersensitivity reactions to omalizumab

Current Drug Safety

Volumn 6, Issue 5, 2011, Pages 339-342

  Owens, Gregory ^a   Petrov, Andrej ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Asthma; Desensitization; Hypersensitivity; Omalizumab

Indexed keywords

DIPHENHYDRAMINE; OMALIZUMAB; PREDNISONE; STEROID; TRIAMCINOLONE;

ADULT; ANGIONEUROTIC EDEMA; ARTICLE; ASTHMA; CASE REPORT; CLINICAL ASSESSMENT; COUGHING; DESENSITIZATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HOSPITAL; HUMAN; OUTPATIENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPIROMETRY; STEROID THERAPY; TACHYCARDIA; UNIVERSITY; URTICARIA;

ADULT; AMBULATORY CARE; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84855853110     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488611798918692     Document Type: Article

References (18)

1. Busse W, Corren J, Lanier BQ, et al. Omalizumab, Anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108(2); 184-90.
2. Solèr M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18(2); 254-61.
3. Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60(3); 302-8.
4. Romano C, Sellitto A, De Fanis U, et al. Maintenance of remission with low-dose omalizumab in long-lasting, refractory chronic urticaria. Ann Allergy Asthma Immunol. 2010; 104(1); 95-7.
5. Douglass JA, Carroll K, Voskamp A, Bourke P, Wei A, O'Hehir RE. Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient. Allergy 2010; 65(7); 926-7.
6. Lane JE, Cheyney JM, Lane TN, Kent DE, Cohen DJ. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006; 54; 68-72.
7. Casale TB, Bernstein IL, Busse WW, LaForce CF, Tinkelman DG, Stoltz RR, et. al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997; 100(1); 110-21.
8. Casale TB, Stokes J. Anti-IgE therapy: clinical utility beyond asthma. J Allergy Clin Immunol 2009; 123(4); 770-1. e1.
9. Cox L; Platts-Mills TA, Finegold I, Schwartz LB, Simons FE, Wallace DV. American Academy of Allergy, Asthma&Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 2007; 120(6); 1373-7.
10. Genentech, Inc. Xolair (omalizumab) [product insert]. South San Francisco; 2007.
11. Pruzansky JJ, Patterson R. Desensitization of human basophils with suboptimal concentrations of agonist. Evidence for reversible and irreversible desensitization. Immunology. 1988; 65(3); 443-7.
12. MacGlashan D Jr, Lichtenstein LM. Basic characteristics of human lung mast cell desensitization. J Immunol. 1987; 139(2); 50.
13. Paolini R, Numerof R, Kinet JP. Phosphorylation/dephosphorylation of high-affinity IgE receptors: a mechanism for coupling/uncoupling a large signaling complex. Proc Natl Acad Sci U S A 1992; 89(22); 10733-7.
14. Naclerio R, Mizrahi EA, Adkinson NF. Immunologic observations during desensitization and maintenance of clinical tolerance to penicillin. J Allergy Clin Immunol 1983; 71(3); 294-301.
15. Morales AR, Shah N, Castells M. Antigen-IgE desensitization in signal transducer and activator of transcription 6-deficient mast cells by suboptimal doses of antigen. Ann Allergy Asthma Immunol 2005; 94(5); 575-80.
16. Brennan PJ, Rodriguez Bouza T, Hsu FI, Sloane DE, Castells MC. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol 2009; 124(6); 1259-66.
17. Dreyfus DH, Randolph CC. Characterization of an anaphylactoid reaction to omalizumab. Ann Allergy Asthma Immunol 2006; 96(4); 624-7.
18. Price KS, Hamilton RG. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc 2007; 28(3): 313-9.